Literature DB >> 18566243

5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy.

Ludovic Bourré1, Francesca Giuntini, Ian M Eggleston, Michael Wilson, Alexander J MacRobert.   

Abstract

Intracellular porphyrin generation following administration of 5-aminolaevulinic acid (ALA) has been widely used in photodynamic therapy for a range of malignant and nonmalignant lesions. However, ALA is relatively hydrophilic and lacks stability at physiologic pH, limiting its bioavailability. We have investigated more lipophilic, uncharged ALA-peptide prodrugs based on phenylalanyl-ALA conjugates, which are water soluble and chemically stable for improving ALA delivery. Pharmacokinetics of the induced protoporphyrin IX (PpIX) were studied in transformed PAM212 keratinocyte cells and pig skin explants. The intracellular porphyrin production was substantially increased with Ac-L-Phe-ALA-Me (compound 1) and Ac-L-Phe-ALA (compound 3) compared with equimolar ALA: after 6-h incubation, the PpIX fluorescence measured using 0.01 mmol/L of compound 1 was enhanced by a factor of 5 compared with ALA. Phototoxicity results showed good correlation with PpIX levels, giving a LD(50) (2.5 J/cm(2)) of 25 micromol/L for ALA, 6 micromol/L for 5-aminolaevulinic hexyl ester, and 2.6 micromol/L for compound 1, which exhibited the highest phototoxicity. However, these results were stereospecific because the corresponding D-enantiomer, Ac-D-Phe-ALA-Me (compound 2), induced neither porphyrin synthesis nor phototoxicity. PpIX levels were considerably reduced when cells were incubated with compound 1 at low temperatures, consistent with active transport. In pig skin explants, compound 1 induced higher porphyrin fluorescence than ALA by a factor of 3. These results show that water-soluble peptide prodrugs of ALA can greatly increase its cellular uptake, generating more intracellular PpIX and improved tumor cell photosensitization. The derivatives are comparable in efficacy with 5-aminolaevulinic hexyl ester but less toxic and more stable at physiologic pH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566243     DOI: 10.1158/1535-7163.MCT-08-0092

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

Review 1.  Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting.

Authors:  Muhammad Abdur Rahim; Nasrullah Jan; Safiullah Khan; Hassan Shah; Asadullah Madni; Arshad Khan; Abdul Jabar; Shahzeb Khan; Abdelbary Elhissi; Zahid Hussain; Heather C Aziz; Muhammad Sohail; Mirazam Khan; Hnin Ei Thu
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

2.  Expression of Genes Involved in Porphyrin Biosynthesis Pathway in the Human Renal Cell Carcinoma.

Authors:  Hugo Nóbrega da Rocha Filho; Evelin Caroline da Silva; Flávia R O Silva; Lilia Coronato Courrol; Carlos Henrique de Mesquita; Maria Helena Bellini
Journal:  J Fluoresc       Date:  2015-08-06       Impact factor: 2.217

3.  Poly(L-histidine)-tagged 5-aminolevulinic acid prodrugs: new photosensitizing precursors of protoporphyrin IX for photodynamic colon cancer therapy.

Authors:  Renjith P Johnson; Chung-Wook Chung; Young-Il Jeong; Dae Hwan Kang; Hongsuk Suh; Il Kim
Journal:  Int J Nanomedicine       Date:  2012-05-17

Review 4.  Recent advances in innovative strategies for enhanced cancer photodynamic therapy.

Authors:  Tingting Hu; Zhengdi Wang; Weicheng Shen; Ruizheng Liang; Dan Yan; Min Wei
Journal:  Theranostics       Date:  2021-01-15       Impact factor: 11.556

Review 5.  Current status of photodynamic technology for urothelial cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Atsushi Kurabayashi; Mutsuo Furihata; Kazuhiro Hanazaki; Hung Wei Lai; Shun-Ichiro Ogura
Journal:  Cancer Sci       Date:  2021-12-02       Impact factor: 6.716

6.  Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism.

Authors:  L Bourré; F Giuntini; I M Eggleston; M Wilson; A J MacRobert
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.